title: Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
abstract: OBJECTIVE
  The objective was to study in vivo erythropoietin (Epo) progenitor cell surface receptors (EpoR) in the bone marrow (BM) after phlebotomy and bone marrow ablation.
  
  
  METHODS
  Serial tracer interaction method experiments were conducted in adult sheep at baseline and after phlebotomy (PH) and ablation (AB). PH was done 10 days after phlebotomy (to 3-4 g/dl Hb), and the AB was done 8 days after a 3-day oral treatment with bulsulfan (11 mg/kg/day).
  
  
  RESULTS
  Bone marrow ablation changed the elimination from non-linear to linear, consistent with an abolition of the non-linear elimination via BM EpoRs. The phlebotomy increased the linear clearance of the ablated elimination pathway (from 63.6+/-12 to 126+/-64 ml/h/kg), consistent with an up-regulation of the erythroid progenitor BM-based EpoR pool, but did not change the clearance of the non-ablated elimination pathway (p>0.05). The EpoR pool size remaining after BM ablation was 7.4+/-2.7% of the pre-ablation pool.
  
  
  CONCLUSIONS
  Erythropoietin elimination via EpoR in the bone marrow was non-linear and increased following phlebotomy-induced anemia. This is consistent with an up-regulation of the erythropoietic EpoR pool in BM. Assuming that the elimination of Epo after BM ablation was via non-hematopoietic EpoR, then this post-ablation EpoR population was not significantly up-regulated by the phlebotomy.
authors.affiliation: The College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA. veng@uiowa.edu
authors.forename: P
authors.initials: P
authors.lastname: Veng-Pedersen
authors.forename: S
authors.initials: S
authors.lastname: Chapel
authors.forename: N H
authors.initials: NH
authors.lastname: Al-Huniti
authors.forename: R L
authors.initials: RL
authors.lastname: Schmidt
authors.forename: E M
authors.initials: EM
authors.lastname: Sedars
authors.forename: R J
authors.initials: RJ
authors.lastname: Hohl
authors.forename: J A
authors.initials: JA
authors.lastname: Widness
mesh_terms: D000477:Alkylating Agents / Q000494:pharmacology; D000740:Anemia / Q000209:etiology / Q000378:metabolism*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism; D002066:Busulfan / Q000494:pharmacology; D017115:Catheter Ablation; D004921:Erythropoietin / Q000097:blood / Q000493:pharmacokinetics*; D006207:Half-Life; D008657:Metabolic Clearance Rate; D018962:Phlebotomy; D017467:Receptors, Erythropoietin / Q000378:metabolism*; D011994:Recombinant Proteins; D012756:Sheep
chemical_list: D000477:Alkylating Agents; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D004921:Erythropoietin; D002066:Busulfan